AZT ArcticZymes Technologies ASA
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools market, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.…
Industry Peers
BiotechnologyKey Statistics
About ArcticZymes Technologies (OSL: AZT)
›
ArcticZymes Technologies (OSL: AZT) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 50 employees.
The shares were at 21.10 NOK on 19 November 2026, down 12.4% over 52 weeks. Its 52-week range is 18.30 NOK to 26.60 NOK: the price is 20.7% below the high and 15.3% above the low.
At a market capitalisation of 1.08B NOK, it trades at 78.1 times trailing earnings and 43.0 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 133% for AZT.
ArcticZymes Technologies reports return on equity of 2.9%, an operating margin of 8.0% and revenue up 11.1% year over year.
It holds more cash than debt, a net cash position of 253.74M NOK. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. One analyst covers the stock, with an average rating of Buy; their mean price target of 27.00 NOK is 28.0% above the current price. The next earnings report is expected on 11 February 2027.